FLT3 and acute myeloid leukemia: Demethylation medicines, IDH inhibitors, FLT3 inhibitors, and BCL-2 inhibitors are just a few medications that have recently been developed as a result of an improved understanding of the pathogenic pathways causing AML, including genetic characteristics and epigenetic changes.